| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-03-15 |
| タイトル |
|
|
タイトル |
Pretreatment Cytokine Signatures as Candidate Biomarkers for JAK Inhibitor Response in Anti‐MDA5 Dermatomyositis–Related Interstitial Lung Disease: A Pilot Study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Matsuo, Haruna
Koga, Tomohiro
Shimizu, Toshimasa
Ide, Hiroyuki
Koto, Serina
Kojima, Kanako
Fujita, Yuya
Okamoto, Momoko
Takatani, Ayuko
Suzuki, Takahisa
Matsushita, Yuta
Kawakami, Atsushi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objective: To evaluate the clinical characteristics and serum cytokine profiles of patients with anti-MDA5 antibody–positive dermatomyositis with interstitial lung disease (MDA5+ DM-ILD) treated with JAK inhibitors and to compare survivors and nonsurvivors. Methods: Six patients diagnosed with MDA5+ DM-ILD at Nagasaki University Hospital (from 2018 to 2023) were analyzed. All patients received high-dose glucocorticoids, intravenous cyclophosphamide, and plasma exchange. Five patients received calcineurin inhibitors. JAK inhibitors (tofacitinib, n = 3; baricitinib, n = 3) were added to the treatment regimen. Clinical data, including serum ferritin levels, hypoxemia status, and lymphocyte counts, were recorded at initial presentation and during JAK inhibitor treatment. Serum cytokine levels were analyzed using multiplex assays. Results: The mean patient age was 66.6 years, and four patients were women. Three patients died within six months of starting JAK inhibitor therapy. Nonsurvivors had higher initial ferritin levels than survivors (mean 3,413 vs 809 ng/mL). Hypoxemia was present in five patients at JAK inhibitor initiation, and four patients had low lymphocyte counts. Serum cytokine analysis revealed elevated levels of granulocyte colony-stimulating factor, interferon-α, interleukin-4, interleukin-13, and CXCL8 in nonsurvivors compared with survivors. Conclusions: Serum cytokine profiles may serve as prognostic markers in patients with MDA5+ DM-ILD treated with JAK inhibitors. The persistent elevation of multiple cytokines in nonsurvivors may reflect inadequate suppression of the cytokine storm despite treatment. Further research is needed to determine the optimal selection and timing of JAK inhibitor therapy. |
|
言語 |
en |
| 書誌情報 |
en : ACR Open Rheumatology
巻 8,
号 2,
p. art. no. e90002,
発行日 2026-02-19
|
| 出版者 |
|
|
出版者 |
John Wiley and Sons Inc |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2578-5745 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1002/acr2.90002 |
| 権利 |
|
|
権利情報 |
© 2026 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
ACR Open Rheumatology, 8(2), art. no. e90002; 2026 |
|
言語 |
en |
ACROR8_e90002.pdf (277 KB)
